Manny M. Semonis

Manny M. Semonis

Auto-generated profile, based on publicly available information

Manny M. Semonis

Department of Chemistry

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Biochemistry
Verified
Journal Article
Closed access
JJJason C. Jones
Jason C. Jones
RBRahul Banerjee
Rahul Banerjee
KSKe Shi
Ke Shi
MSManny M. Semonis
Manny M. Semonis
HAHideki Aihara
Hideki Aihara
JLJohn D. Lipscomb
John D. Lipscomb


19 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DRDamien M. Rasmussen
Damien M. Rasmussen
MSManny M. Semonis
Manny M. Semonis
JGJoseph T. Greene
Joseph T. Greene
JMJoseph M. Muretta
Joseph M. Muretta
ATAndrew R. Thompson
Andrew R. Thompson
NLNicholas M. Levinson
Nicholas M. Levinson
The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.

18 February 2026 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
VEVanessa H. Eng
Vanessa H. Eng
SNSarah M. Narehood
Sarah M. Narehood
YLYiying Li
Yiying Li
MGMauro Gascón
Mauro Gascón
AHAlexander M. Hoffnagle
Alexander M. Hoffnagle
FTF. Akif Tezcan
F. Akif Tezcan

3 April 2024 in eLife preprints
Verified
Preprint
Open access
DRDamien M. Rasmussen
Damien M. Rasmussen
MSManny M. Semonis
Manny M. Semonis
JGJoseph T. Greene
Joseph T. Greene
JMJoseph M. Muretta
Joseph M. Muretta
ATAndrew R. Thompson
Andrew R. Thompson
NLNicholas M. Levinson
Nicholas M. Levinson
The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.